StockData

Adagene vs BioAge Labs

ADAG and BIOA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADAG and BIOA compare

Adagene grew revenue faster over the last twelve months (7333% versus 168% for BioAge Labs).

Adagene keeps more of each dollar of sales as profit, with a net margin of −230% compared with −912% at BioAge Labs.

BioAge Labs scores higher on the StockData Score (8 against 5 for Adagene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADAGBIOA
Size and price
Market cap–$240M
Share price$1.60$5.22
Change, 1 year−11.1%−32.4%
Change, 5 years−81.6%–
Beta (5Y)0.612.40
Employees12862
StockData Score
Total score58 (better)
Valuation score01 (better)
Growth score11
Performance score2 (better)1
Health score25 (better)
Dividend score00
Valuation
P/S–23.1×
P/B–0.6×
FCF yield–−36.8%
Growth
Revenue growth (TTM)7333% (better)168%
Revenue growth, 5Y average61.4%–
Profitability
Operating margin−279% (better)−1026%
Net margin−230% (better)−912%
FCF margin−204% (better)−851%
Return on equity−27.7% (better)−28.2%
Return on invested capital–−283%
Financial health
Debt / equity0.06 (better)0.00
Interest coverage−46.3× (better)−378.2×
Current ratio5.0217.19 (better)
Altman Z-score–5.27
Piotroski F-score44
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions32.5%82.2%
Held by insiders16.8%21.9%
Insider net buying, 12 months$162K (better)−$7.8M
Short interest, % of float–10.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.